The first Kazakh-American venture fund, FutureMED Ventures KZ, has been launched in the USA.

The first Kazakh-American venture fund for innovative medical technologies, FutureMED Ventures KZ, was launched in the state of Delaware. This state is known for its advanced corporate law legislation. The total planned size of the fund is $400 million.

The FutureMED Ventures KZ team includes renowned American and Kazakhstani specialists in the commercialization of scientific developments in biomedicine and medical devices. The fund is engaged in searching for and selecting companies developing promising innovative technologies in the field of medicine, followed by financing clinical trials of these technologies in exchange for shares in these companies.

If clinical trials are successfully completed, the value of the company can increase by tens of times, depending on the size of the market for the disease that the technology aims to treat, as well as the degree of proven efficacy.

The fund's management has developed a unique concept for transforming Kazakhstan into a research hub by conducting clinical trials in Kazakhstani medical institutions. The domestic healthcare system can offer significantly lower costs for conducting clinical trials and in much shorter timeframes.

The unique strategy of the FutureMED Ventures KZ fund is aimed at developing the domestic clinical trials market.

Source: kapital.kz